Base de dados : LILACS
Pesquisa : C12.777.419 [Categoria DeCS]
Referências encontradas : 1277 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 128 ir para página                         

  1 / 1277 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-1292126
Autor: Grandi, Carlos.
Título: Desarrollo renal fetal alterado y riesgo aumentado de enfermedades del adulto / Alterations in fetal kidney development and increased risk for adult diseases
Fonte: Arch. argent. pediatr;119(5):e480-e486, oct. 2021. ilus.
Idioma: en; es.
Resumo: El bajo peso al nacer (BP, < 2500 g), la restricción del crecimiento intrauterino (RCIU) y el parto prematuro (PP, < 37 semanas de gestación) son los factores clínicos más habituales para la programación alterada del número de nefronas y se asocian con un mayor riesgo de hipertensión, proteinuria y enfermedad renal futura en la vida. En la actualidad la evaluación indirecta del número total de nefronas mediante el uso de marcadores en el período posnatal representa el enfoque principal para evaluar el riesgo de evolución futura de los trastornos renales en los recién nacidos con BP, RCIU o PP.Se presentan los avances en la investigación en animales y sobre marcadores bioquímicos en humanos, y recomendaciones para la prevención del daño renal preconcepcional, incluidos los factores sociales y las enfermedades crónicas. La evidencia demuestra que la restricción de crecimiento y la prematuridad solas son capaces de modular la nefrogénesis y la función renal y, cuando son concurrentes, sus efectos tienden a ser acumulativos.

A low birth weight (LBW, < 2500 g), intrauterine growth restriction (IUGR), and preterm birth (PB, < 37 weeks of gestational age) are the most common clinical factors for an altered programming of nephron number and are associated with a greater risk for hypertension, proteinuria, and kidney disease later in life. At present, an indirect assessment of total nephron number based on postnatal markers is the most important approach to evaluate the risk for future kidney disorders in newborn infants with a LBW, IUGR or PB.Here we describe advances made in animal experiments and biochemical markers in humans, and the recommendations for the prevention of preconception kidney injury, including social factors and chronic diseases. According to the evidence, IUGR and prematurity alone can modulate nephrogenesis and kidney function, and, if occurring simultaneously, their effects tend to be cumulative.
Descritores: Nascimento Prematuro
Nefropatias/etiologia
Nefropatias/epidemiologia
-Recém-Nascido de Baixo Peso
Idade Gestacional
Rim
Néfrons
Limites: Humanos
Animais
Feminino
Gravidez
Recém-Nascido
Adulto
Responsável: AR94.1 - Centro de Información Pediatrica


  2 / 1277 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1153519
Autor: Sun, Mengkui; Zhou, Wei; Yao, Fei; Song, Jianming; Xu, Yanan; Deng, Zhimei; Diao, Hongwang; Li, Shoulin.
Título: MicroRNA-302b mitigates renal fibrosis via inhibiting TGF-ß/Smad pathway activation
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;54(3):e9206, 2021. graf.
Idioma: en.
Resumo: Renal fibrosis is one of the most significant pathological changes after ureteral obstruction. Transforming growth factor-β (TGF-β) signaling pathway plays essential roles in kidney fibrosis regulation. The aims of the present study were to investigate effects of microRNA-302b (miR-302b) on renal fibrosis, and interaction between miR-302b and TGF-β signaling pathway in murine unilateral ureteral obstruction (UUO) model. Microarray dataset GSE42716 was downloaded by retrieving Gene Expression Omnibus database. In accordance with bioinformatics analysis results, miR-302b was significantly down-regulated in UUO mouse kidney tissue and TGF-β1-treated HK-2 cells. Masson's trichrome staining showed that miR-302b mimics decreased renal fibrosis induced by UUO. The increased mRNA expression of collagen I and α-smooth muscle actin (α-SMA) and decreased expression of E-cadherin were reversed by miR-302b mimics. In addition, miR-302b up-regulation also inhibited TGF-β1-induced epithelial mesenchymal transition (EMT) of HK-2 cells by restoring E-cadherin expression and decreasing α-SMA expression. miR-302b mimics suppressed both luciferase activity and protein expression of TGF-βR2. However, miR-302b inhibitor increased TGF-βR2 luciferase activity and protein expression. Meanwhile, miR-302b mimics inhibited TGF-βR2 mRNA expression and decreased Smad2 and Smad3 phosphorylation in vivo and in vitro. Furthermore, over-expression of TGF-βR2 restored the miR-302b-induced decrease of collagen I and α-SMA expression. In conclusion, this study demonstrated that miR-302b attenuated renal fibrosis by targeting TGF-βR2 to suppress TGF-β/Smad signaling activation. Our findings showed that elevating renal miR-302b levels may be a novel therapeutic strategy for preventing renal fibrosis.
Descritores: Obstrução Ureteral/patologia
Transdução de Sinais
Fator de Crescimento Transformador beta/metabolismo
MicroRNAs/genética
Proteínas Smad
Nefropatias/genética
-Fibrose
Linhagem Celular
Transição Epitelial-Mesenquimal
Rim/patologia
Nefropatias/patologia
Limites: Humanos
Animais
Ratos
Responsável: BR1.1 - BIREME


  3 / 1277 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-951983
Autor: Moro, Marcella Goetz; Sanchez, Paula Katherine Vargas; Gevert, Mayara Vitorino; Baller, Emeline Maria; Tostes, Ana Flávia; Lupepsa, Ana Caroline; Baglie, Sinvaldo; Franco, Gilson Cesar Nobre.
Título: Gastric and renal effects of COX-2 selective and non-selective NSAIDs in rats receiving low-dose aspirin therapy
Fonte: Braz. oral res. (Online);30(1):e127, 2016. tab, graf.
Idioma: en.
Resumo: Abstract The consumption of low-dose aspirin (LDA) to prevent cardiovascular disease continues to increase worldwide. Consequently, the number of chronic LDA users seeking dental procedures that require complementary acute anti-inflammatory medication has also grown. Considering the lack of literature evaluating this interaction, we analyzed the gastric and renal effects caused by a selective COX-2 inhibitor (etoricoxib) and a non-selective COX-2 inhibitor (ibuprofen) nonsteroidal anti-inflammatory drug (NSAID) in rats receiving chronic LDA therapy. Male Wistar rats were divided into six experimental groups (carboxymethylcellulose (CMC) - vehicle; LDA; LDA + ibuprofen; ibuprofen; LDA + etoricoxib; and etoricoxib) and submitted to long-term LDA therapy with a subsequent NSAID administration for three days by gavage. After the experimental period, we analyzed gastric and renal tissues and quantified serum creatinine levels. The concomitant use of LDA with either NSAID induced the highest levels of gastric damage when compared to the CMC group (F = 20.26, p < 0.05). Treatment with either LDA or etoricoxib alone was not associated with gastric damage. No significant damage was observed on kidney morphology and function (F = 0.5418, p > 0.05). These results suggest that even the acute use of an NSAID (regardless of COX-2 selectivity) can induce gastric damage when combined with the long-term use of low-dose aspirin in an animal model. Additional studies, including clinical assessments, are thus needed to clarify this interaction, and clinicians should be careful of prescribing NSAIDs to patients using LDA.
Descritores: Inibidores da Agregação Plaquetária/administração & dosagem
Anti-Inflamatórios não Esteroides/efeitos adversos
Aspirina/administração & dosagem
Inibidores de Ciclo-Oxigenase 2/efeitos adversos
Mucosa Gástrica/efeitos dos fármacos
Rim/efeitos dos fármacos
-Piridinas/efeitos adversos
Gastropatias/induzido quimicamente
Sulfonas/efeitos adversos
Fatores de Tempo
Doenças Cardiovasculares/prevenção & controle
Distribuição Aleatória
Ibuprofeno/efeitos adversos
Fatores de Risco
Resultado do Tratamento
Ratos Wistar
Creatinina/sangue
Etoricoxib
Nefropatias/induzido quimicamente
Limites: Animais
Masculino
Responsável: BR1.1 - BIREME


  4 / 1277 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Uruguai
Texto completo
Texto completo
Id: biblio-1180955
Autor: Silvariño, Ricardo; Boggia, José; Seija, Mariana; Baccino, Cecilia; Román, Sofía San; Luzardo, Leonella; López, Martín; Frantchez, Victoria; Ferreiro, Alejandro; Otatti, Gabriela; Parnizzari, Paula; Miller, David; Yandian, Federico; Guerisoli, Ana; Miranda, Verónica; Fernández, Sofía; González, Xosé; Noboa, Agustín; Villegas, Natalia; Gauronas, Paula; Nin, Marcelo; Nin, Nicolás; Larre Borges, Patricia; Tobal, Diego; Álvarez, Asunción; Ríos, Pablo; Cabrera, Jimena; Noboa, Óscar.
Título: Recomendaciones para la actuación clínica y organización asistencial durante la pandemia por SARS-CoV-2 en nefrología / Recommendations for clinical action and healthcare organization during the SARS-CoV-2 pandemic in nephrology / Recomendações para ação clínica e organização da assistência médica durante a pandemia de SARS-CoV-2 em nefrologia
Fonte: Rev. méd. Urug;36(2):219-238, 2020. tab, graf.
Idioma: es.
Descritores: Cobertura Efetiva de Serviços de Saúde/organização & administração
COVID-19
Nefropatias
-Pandemias
Responsável: UY6.1 - Biblioteca


  5 / 1277 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: lil-737709
Autor: Gutierrez Mendez, José; Rocabado Guzmán, Mery; Rueda Guzmán, Elizabeth; Rocabado Guzmán, Wilmer; Guzmán Gómez, Orlando.
Título: Incidencia de la nefropatía como causa de insuficiencia renal crónica terminal / Incidence of nephropathy as a cause of end-stage renal disease
Fonte: Gac. méd. boliv;28(2):25-30, 2005. ilus.
Idioma: es.
Resumo: La Nefropatía Diabética (ND) es la complicación mas temida en la evolución de la diabetes mellitus, por la elevada morbi - mortalidad y costos de su mantenimiento; se le suman progresivamente la retinopatía, neuropatía periférica, vasculopatia micro y macroangiopática discapacitante, disautonomia gastrointestinal y el elevado riesgo de complicaciones infecciosas. El presente estudio descriptivo, retrospectivo y analítico, se realizó en las Unidades de Hemodiálisis y Diálisis Peritoneal de los Hospitales Viedma y Cushieri, de Cochabamba. Nuestro objetivo es determinar la importancia de la detección precoz de la ND para la prevención de insuficiencia renal crónica terminal (IRCT) y el impacto social, económico y humano que esta conlleva. Se tomó en cuenta 60 pacientes diabéticos de 188 pacientes que se encontraban en tratamiento dialítico. El 98% de ellos tenía diabetes tipo II y 2% con diabetes tipo I: el 100% de ellos cursaba con Insuficiencia renal crónica (IRC) estadio III - IV. Un 52% no tuvo seguimiento médico hasta el momento del desarrollo de la uremia e ingresó a tratamiento dialítico de urgencia. Del total de pacientes en estudio 22 (37%) permanecen aun en control pre - dialítico, 38 (63%) están dentro del programa de diálisis de los cuales 29 (76%) se encuentran en diálisis peritoneal y 9 (24%) en hemodiálisis. En cuanto al seguimiento del tratamiento dialítico un 24% abandonaron el tratamiento por falta de recursos económicos, un 37% fue referido a su seguro social y un 39% continúa en tratamiento.

The Diabétic Nefropatía (ND) is a complication feared in the evolution of Diabetes Mellitus, for the elevated morbi - mortality and costs of his maintenance, in addition the progressive retinopathy, peripheal Neuropatía, micro and macroangiopatica vasculopathy discapacitante, gastrointestinal disautonomia and the elevated risk of infectious complications. The present paper is descriptive, retrospective and analytical, the study was done in the Hospitals Hemodiálisis's and Diálisis P Titoneal's units of the Viedma and Cuschieri, of Cochabamba. Our objective is to determine the importance of early detection of the ND for the prevention of the terminal renal insufficiency (IRCT) and the social, economic and human impact that this one bears. The universe was 188 patients's, 60 diabetic patient were taken into account, and they were finded themselves in dialytic treatment. The 98 % of they had diabetes type II and 2 % with diabetes type I, the 100 % of they were with renal chronic Insuficiencia (IRC) stage III - IV. A 52 % they did not have medical treatment until the development of uremia and they entered to dialytic treatment of urgency. Of patients's under consideration the total 22 (37 %) they remain in Pre - dialytic control, 38 (63 %) come within the program of dialysis of them as 29 (76 %) were in peritoneal dialysis and 9 (24 %) in Hemodiálysis. In as much as the treatment for lack of economic resources, a 37 % were referred to his social security Hospital and a 39 % continue treatment.
Descritores: Nefropatias
Responsável: BO4.1 - Biblioteca Julio Rodríguez Rivas


  6 / 1277 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1058388
Autor: Parada Zuluaga, Juan Sebastián; Marisancén Carrasquilla, Kelly; Vélez Granda, Aura María; Saldarriaga Giraldo, C. I; Quintero Ossa, Álvaro Mauricio; Cañas Arenas, Eliana Mabel; Agudelo, Adriana María.
Título: Predictores de hospitalización prolongada en pacientes con insuficiencia cardiaca aguda / Predictors of prolonged hospital stay in patients with acute heart failure
Fonte: Rev. colomb. cardiol;26(2):78-85, mar.-abr. 2019. tab.
Idioma: es.
Resumo: Resumen Introducción: la insuficiencia cardiaca aguda es la principal causa de hospitalización en adultos mayores de 65 años. La duración de las hospitalizaciones es un determinante del incremento en los costos por la atención hospitalaria. Objetivo: describir el perfil clínico de los pacientes hospitalizados por insuficiencia cardiaca aguda en un centro de referencia cardiovascular e identificar la duración de la estancia hospitalaria y los predictores de una hospitalización prolongada. Métodos: estudio observacional analítico, cohorte, prospectivo. Resultados: durante siete meses se incluyeron 251 pacientes con diagnóstico de insuficiencia cardiaca aguda. La mediana de edad fue de 71 años, fracción de eyección del ventrículo izquierdo de 25%, clasificación Nohria-Stevenson: húmedo-caliente 78,9%; húmedo-frío 15,1%; seco-caliente 2,8% y seco-frío 2,8%. El 15,9% de los pacientes requirieron inotrópicos y 1,2% vasopresores. Las complicaciones más frecuentes fueron el desarrollo de enfermedad renal aguda 33,1% y fibrilación auricular de novo 5,2%. La mediana de estancia hospitalaria fue de 5 días y el 65,7% presentó estancia prolongada (≥7 días). El análisis bivariado mostró predictores de estancia prolongada como requerimiento inotrópico (RR 2,41; IC 95% 1,77-3,27 p 0,000), clasificación Nohria-Stevenson seco-frío y húmedo-frío (RR 1,86; I 95%. 1,33-2,61 p 0,001), clasificación NYHA III-IV (RR 1,85; IC 95% 1,06-3,24 p 0,017), enfermedad renal aguda (RR 1,82; IC 95% 1,31-2,55 p 0,000) y diabetes mellitus (RR 1,47; IC 95% 1,05-2,06 p 0,026). Conclusión: en una población con predominio de función cardíaca reducida y múltiples comorbilidades, la mediana de hospitalización por insuficiencia cardiaca aguda fue de 5 días. Se identificaron como predictores de estancia prolongada el soporte inotrópico, la clasificación Nohria-Stevenson seco-frío y húmedo-frío, NYHA III-IV, la enfermedad renal aguda y la diabetes mellitus.

Abstract Introduction: Acute heart failure is the main cause of hospital admission in adults over 65 years-old. The length of the hospital stay is a determining factor in the increase in the costs of hospital care. Objective: To describe the clinical profile of patients admitted to hospital Cardiovascular Reference Centre due to acute heart failure and to determine the duration of the hospital stay and the predictors of prolonged admission. Methods: A prospective, analytical, observational, cohort study. Results: A total of 251 patients with a diagnosis of acute heart failure were admitted during a six-month period. The median age was 75 years, with a mean left ventricle ejection fraction of 25%, and a Nohria-Stevenson classification: wet-hot 78.9%; wet-cold 15.1%; dry-hot 2.8%, and dry-cold 2.8%. Inotropes were required by 15.9% of patients and vasopressors by 1.2%. The most frequent complications were development of acute kidney disease in 33.1%, and de novo atrial fibrillation in 5.2%. The median hospital stay was 5 days, and 65.7% had a prolonged stay (≥7 days). The bivariate analysis showed prolonged stay predictors such as inotrope requirement (RR 2.41; 95% CI; 1.77-3.27, P = .000), a Nohria-Stevenson classification of dry-cold and wet-cold (RR 1.86; 95% CI; 1.33-2.61, P = .001), NYHA classification of III-IV (RR 1.85; 95% CI; 1.06-3.24, P = .017), acute kidney disease (RR 1.82; 95% CI; 1.31-2.55, P = .000), and diabetes mellitus (RR 1.47; 95% CI; 1.05-2.06, P = .026). Conclusion: In a population with a predominance of reduced cardiac function and multiple comorbidities, the median hospital stay due to acute heart failure was 5 days. Predictors of a prolonged stay were identified as inotrope support, a Nohria-Stevenson classification of dry-cold and wet-cold, NYHA III-IV, acute kidney disease, and diabetes mellitus.
Descritores: Nível de Saúde
Assistência Hospitalar
Insuficiência Cardíaca
-Fibrilação Atrial
Ventrículos do Coração
Hospitalização
Nefropatias
Limites: Humanos
Masculino
Feminino
Idoso
Responsável: CO369.9 - SCC - Sociedad Colombiana de Cardiologia y Cirugía Cardiovascular


  7 / 1277 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1004743
Autor: Sargin, Gokhan; Kose, Reyhan; Senturk, Taskin.
Título: Anti-interleukin-1 treatment among patients with familial Mediterranean fever resistant to colchicine treatment. Retrospective analysis
Fonte: Säo Paulo med. j;137(1):39-44, Jan.-Feb. 2019. tab.
Idioma: en.
Resumo: ABSTRACT BACKGROUND: Up to 5% of familial Mediterranean fever (FMF) cases are unresponsive to colchicine, through resistance, side effects and toxicity. Anakinra is an alternative treatment for FMF patients whose disease remains uncontrolled with colchicine. We aimed to evaluate anti-interleukin-1 treatment regarding clinical findings, laboratory parameters and quality of life (QoL) among FMF patients presenting resistance and toxicity towards colchicine. DESIGN AND SETTING: Descriptive observational study at the rheumatology clinic, Adnan Menderes University Medical School, Aydın, Turkey. METHODS: Among the patients included, age, sex, MEFV genotypes, acute-phase reactants, hepatic/renal function tests, average colchicine dose, disease duration, attack frequency, attack duration, disease severity, proteinuria, amyloidosis and QoL were evaluated. Colchicine resistance was defined as > 6 typical episodes/year or > 3 per 4-6 months. Kolmogorov-Smirnov, Friedman and two-way analysis of variance tests were used for statistical analyses. RESULTS: Between 2015 and 2017, 14 FMF patients receiving anakinra were enrolled. The mean colchicine dose was 1.7 ± 0.3 mg/day before use of anakinra. Ten patients were attack-free after treatment, while three showed reductions of at least 50% in attack frequency, attack duration and disease severity. Proteinuria levels in all patients with renal amyloidosis decreased after treatment. QoL among patients with renal amyloidosis differed significantly from QoL among non-amyloidosis patients. Mean visual analogue scale scores significantly improved in both groups after use of anakinra. CONCLUSIONS: Use of anakinra reduced attack frequency and proteinuria and acute-phase reactant levels, and improved QoL, with only a few uncomplicated side effects among colchicine-resistant or intolerant FMF patients. Injection-site reactions of severity insufficient to require discontinuation of treatment were seen.
Descritores: Febre Familiar do Mediterrâneo/tratamento farmacológico
Qualidade de Vida
Resistência a Medicamentos/efeitos dos fármacos
Colchicina/uso terapêutico
Interleucina-1/antagonistas & inibidores
Antirreumáticos/uso terapêutico
Proteína Antagonista do Receptor de Interleucina 1/uso terapêutico
-Febre Familiar do Mediterrâneo/fisiopatologia
Proteinúria/urina
Valores de Referência
Fatores de Tempo
Turquia
Índice de Gravidade de Doença
Sedimentação Sanguínea
Reprodutibilidade dos Testes
Estudos Retrospectivos
Análise de Variância
Resultado do Tratamento
Estatísticas não Paramétricas
Escala Visual Analógica
Amiloidose/fisiopatologia
Amiloidose/tratamento farmacológico
Nefropatias/fisiopatologia
Nefropatias/tratamento farmacológico
Limites: Humanos
Masculino
Feminino
Adulto
Pessoa de Meia-Idade
Responsável: BR1.1 - BIREME


  8 / 1277 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1154401
Autor: Arsanios, Daniel Martin; Cabezas, Daniel Felipe; Barragán, Andres Felipe; Estupiñán, María Fernanda; Calderón, Carlos Mauricio; Quintero-Muñoz, Elías.
Título: Tercer caso de vasculitis leucocitoclástica cutánea secundaria al uso de oxacilina: reporte de caso / Third case in the literature of cutaneous leukocytoclastic vasculitis secondary to oxacilin use
Fonte: Infectio;25(1):45-48, ene.-mar. 2021. tab, graf.
Idioma: es.
Resumo: Resumen La vasculitis leucocitoclastica es una patologìa que compromete los vasos pequeños y cuya causa predominantemente se ha descrito como idiopatica. Se presenta el caso de una mujer de 78 años hipertensa, diabética y con enfermedad renal crónica en estadio 5, que presentó lesiones limitadas a la piel posterior a la administración de oxacilina para manejo de bacteremia por SAMS. La presentación clínica se basó en purpuras palpables predominantemente en miembros inferiores y lesiones dolorosas coalescentes que formaban ampollas de contenido hemorrágico. Estas lesiones resolvieron gradualmente después del cambio de la terapia mencionada anteriormente. La biopsia fue compatible con vasculitis leucocitoclástica, con paraclínicos que descartaron causas infecciosas y autoinmunes.

Abstract Leukocytoclastic vasculitis is a pathology that involves small vessels and whose cause has been predominantly described as idiopathic. The clinical case of a 78-year-old woman with hypertension, diabetic and chronic stage 5 kidney disease, who presented limited skin lesions after administration of oxacillin for management of bacteremia by MSSA. The clinical presentation consisted on palpable purpura predominantly in the lower limbs and painful coalescent lesions that formed blisters of hemorrhagic content. Lesions gradually resolved after the change of the therapy mentioned above. The biopsy was compatible with leukocytocastic vasculitis, with paraclinics who ruled out infectious and autoimmune causes.
Descritores: Vasculite Leucocitoclástica Cutânea
-Oxacilina
Vesícula
Insuficiência Renal Crônica
Nefropatias
Limites: Humanos
Masculino
Idoso
Tipo de Publ: Relatos de Casos
Responsável: CO359.1 - ACIN - Asociación Colombiana de Infectologia


  9 / 1277 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-1292015
Autor: Pinto, Karina Daneilly Cavalcanti; Cavalcanti, Alessandra do Nascimento; Maia, Eulália Maria Chaves.
Título: Qualidade de vida após o transplante renal: revisão integrativa / Quality of life after kidney transplantation: integrative review / Calidad de vida después del trasplante renal: revisión integrativa
Fonte: Rev. Pesqui. (Univ. Fed. Estado Rio J., Online);13:1388-1394, jan.-dez. 2021. ilus.
Idioma: en; pt.
Resumo: Objective:To analyze how the literature presents the quality of life in renal transplant patients. Methods: base review study: MEDLINE, LILACS and SCIELO. The descriptors kidney Transplantation and quality of life were used, combined with the boolean operator and. After considering the criteria, 15 articles were fully analyzed.Results: the publications showed that the transplantation contributes to the improvement of the patient's quality of life, although, compared to the general population, this quality is lower. Factors such as: presence of comorbidities, transplantation time, educational level and psychological aspects influence the patient's view of their quality of life.Conclusion: the quality of life after transplantation is surrounded by multiple aspects and particularities. Finding the benefits of transplantation for the renal patient does not exempt the possibility of negative dimensions that may compromise the perception of quality of life

Objetivo: Analisar como a literatura apresenta a qualidade de vida em paciente transplantado renal. Métodos: estudo de revisão nas bases: MEDLINE, LILACS e SCIELO. Utilizou-se os descritores "Kidney Transplantation" e "Quality of Life", combinando-se com o operador booleano AND. Após consideração dos critérios, foram analisados integralmente 15 artigos. Resultados: As publicações evidenciaram que o transplante contribui para melhoria da qualidade de vida do paciente, ainda assim, se comparado à população geral essa qualidade é inferior. Fatores como: presença de comorbidades, tempo de transplante, nível de escolaridade e aspectos psicológicos influenciam a visão que o paciente possui da sua qualidade de vida. Conclusão: a qualidade de vida após o transplante é envolta de múltiplos aspectos e particularidades. A constatação dos benefícios do transplante para o doente renal, não isenta a possibilidade da existência de dimensões negativas as quais podem comprometer a percepção da qualidade de vida.

Objetivo: Analizar cómo la literatura presenta la calidad de vida en pacientes con trasplante renal.Métodos: estudio de revisión base: MEDLINE, LILACS y SCIELO. Se utilizaron los descriptores trasplante de riñón y calidad de vida, combinados con el operador booleano and. Después de considerar los criterios, 15 artículos fueron completamente analizados. Resultados: las publicaciones mostraron que el trasplante contribuye a la mejora de la calidad de vida del paciente, aunque, en comparación con la población general, esta calidad es menor. Factores como: presencia de comorbilidades, tiempo de trasplante, nivel educativo y aspectos psicológicos influyen en la visión del paciente sobre su calidad de vida.Conclusión: la calidad de vida después del trasplante está rodeada de múltiples aspectos y particularidades. Encontrar los beneficios del trasplante para el paciente renal no exime la posibilidad de dimensiones negativas que pueden comprometer la percepción de la calidad de vida
Descritores: Qualidade de Vida
Transplante de Rim
Nefropatias/cirurgia
Limites: Humanos
Masculino
Feminino
Tipo de Publ: Revisão
Responsável: BR1208.1 - BSEN - Biblioteca Setorial de Enfermagem e Nutrição


  10 / 1277 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-961383
Autor: Aguirre, Verónica; Alvo, Miriam; Ardiles, Leopoldo; Fierro, Alberto; Goecke, Annelise; Iruretagoyena, Mirentxu; Jalil, Roberto; Massardo, Loreto; Méndez, Gonzalo P; Palma, Sergio; Roessler, Emilio; Silva, Francisco; Wurgaft, Andrés.
Título: Compromiso renal en vasculitis asociadas a anticuerpos anticitoplasma de neutrófilos. Recomendaciones de consenso de las Sociedades Chilenas de Nefrología y Reumatología / Renal involvement in antineutrophil cytoplasmic antibodies (ANCA) associated vasculitides. Recommendations of the Chilean Societies of Nephrology and Rheumatology
Fonte: Rev. méd. Chile;146(2):241-248, feb. 2018.
Idioma: es.
Resumo: Renal involvement is a frequent complication in antineutrophil cytoplasmic antibodies (ANCA)associated vasculitides, adding morbidity and mortality, such as chronic kidney disease and the need for renal replacement therapy. With the aim of reaching a consensus on relevant issues regarding the diagnosis, treatment and follow-up of patients with these diseases, the Chilean Societies of Nephrology and Rheumatology formed a working group that, based on a critical review of the available literature and their experience, raised and answered consensually a set of questions relevant to the subject. This document includes aspects related to the clinical diagnosis, the histological characteristics, the therapeutic alternatives to induce and maintain the remission of the disease, relapse surveillance strategies and complementary therapies.
Descritores: Anticorpos Anticitoplasma de Neutrófilos/sangue
Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/complicações
Nefropatias/etiologia
Nefropatias/terapia
-Sociedades Médicas
Indução de Remissão
Chile
Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/diagnóstico
Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/sangue
Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/terapia
Quimioterapia de Manutenção
Limites: Humanos
Tipo de Publ: Guia de Prática Clínica
Responsável: CL1.1 - Biblioteca Central



página 1 de 128 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde